Welcome to our dedicated page for Synergy Chc SEC filings (Ticker: SNYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When Synergy CHC’s disclosures tuck the story of its detox teas and wellness brands inside dense accounting tables, finding the numbers that move the stock is tough. Our SEC Filings hub solves that problem. Stock Titan’s AI reviews every Synergy CHC quarterly earnings report 10-Q filing and surfaces product-line revenue, marketing spend and cash-flow trends in seconds.
Need a concise overview? Synergy CHC SEC filings explained simply are one click away. AI-powered summaries turn footnotes into plain English, so understanding Synergy CHC SEC documents with AI takes minutes, not hours. Real-time alerts fire the moment a new 8-K posts—giving you Synergy CHC 8-K material events explained. Dashboards stream Synergy CHC insider trading Form 4 transactions, letting you watch executive moves as they happen. The Synergy CHC annual report 10-K simplified highlights inventory cycles and advertising efficiency, while every Synergy CHC earnings report filing analysis updates key ratios automatically.
Use the page like analysts do: monitor Synergy CHC executive stock transactions Form 4 before earnings, compare margins quarter-over-quarter, or read the Synergy CHC proxy statement executive compensation to gauge alignment. If you search “Synergy CHC Form 4 insider transactions real-time,” this is where you’ll land—and leave with decision-ready insight.
- AI-powered summaries that demystify 10-K, 10-Q, 8-K and Form 4 data
- Instant email and RSS alerts for every new filing
- Side-by-side view of historical filings with key metrics highlighted
- Downloadable tables to speed your financial models
Synergy CHC Corp. (SNYR) delivered higher profitability in the second quarter of 2025 while executing material debt refinancing. Revenue for the three months ended June 30, 2025 totaled $8,134,996, including $1,400,000 of license revenue, producing gross profit of $6,238,605. Net income after tax was $1,473,237 for the quarter ($2,349,501 for the six months), driving basic and diluted EPS of $0.17 for the quarter and $0.27 for the six months. Total assets were $19,726,346 with cash and restricted cash of $1,558,561. Total liabilities were $32,105,546, and stockholders' deficit improved to $(12,379,200). In May 2025 the company drew a $17.5 million term loan (with a $2.5 million delayed draw) and used proceeds to repay and restructure prior indebtedness, record a $2,154,522 gain on settlement of notes payable, issue pre-funded warrants and shares in partial debt settlements, and record related debt discounts and issuance costs. Management reported a working capital surplus of $12,383,132 and concluded these actions alleviate substantial doubt about the company’s ability to continue as a going concern for the next twelve months.
Synergy CHC Corp. (SNYR) | Form 4 filed 07/31/2025
CEO/Chairman Jack Ross reported a series of open-market purchases between 06/11/25 and 07/30/25. In 24 separate transactions he bought 27,900 common shares at weighted-average prices ranging from $2.15-$3.90, spending roughly $80k-$90k and increasing his direct stake to 410,507 shares.
Including indirect holdings through four controlled entities—Rosscor Brands (300,000 sh), Gowan Private Equity (3,679,056 sh), Dunhill Distribution (269,635 sh) and Gowan Capital (136,559 sh)—Ross now beneficially owns ≈4.8 million shares.
No sales or derivative transactions were reported. The repeat buying by a 10% owner and key insider may signal confidence ahead of upcoming catalysts, but dollar amounts are modest relative to total market capitalization.
FAQ
What is the current stock price of Synergy Chc (SNYR)?
What is the market cap of Synergy Chc (SNYR)?
